Whole blood
Grainyhead-like 2 (GRHL2)
biomarker
castration-resistant
hormone-sensitive
prostate cancer
Journal
Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
ppublish
Résumé
As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive prostate cancer (mHSPC). The value of whole blood RNA to detect candidate biomarkers in mHSPC remains largely undefined. In this cohort study, we used a previously optimised whole blood reverse transcription polymerase chain reaction assay to assess the prognostic utility [measured by seven-month undetectable prostate-specific antigen (PSA) and time to castration-resistance (TTCR)] of eight prostate cancer-associated gene transcripts in 43 mHSPC patients. Transcripts with statistically significant associations (P<0.05) were further investigated in a metastatic castration-resistant prostate cancer (mCRPC) cohort (n=119) receiving contemporary systemic therapy, exploring associations with PSA >50% response (PSA Detection of circulating Grainyhead-like 2 ( Detectable circulating
Sections du résumé
BACKGROUND
BACKGROUND
As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive prostate cancer (mHSPC). The value of whole blood RNA to detect candidate biomarkers in mHSPC remains largely undefined.
METHODS
METHODS
In this cohort study, we used a previously optimised whole blood reverse transcription polymerase chain reaction assay to assess the prognostic utility [measured by seven-month undetectable prostate-specific antigen (PSA) and time to castration-resistance (TTCR)] of eight prostate cancer-associated gene transcripts in 43 mHSPC patients. Transcripts with statistically significant associations (P<0.05) were further investigated in a metastatic castration-resistant prostate cancer (mCRPC) cohort (n=119) receiving contemporary systemic therapy, exploring associations with PSA >50% response (PSA
RESULTS
RESULTS
Detection of circulating Grainyhead-like 2 (
CONCLUSIONS
CONCLUSIONS
Detectable circulating
Identifiants
pubmed: 33968657
doi: 10.21037/tau-20-1444
pii: tau-10-04-1688
pmc: PMC8100842
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1688-1699Informations de copyright
2021 Translational Andrology and Urology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-1444). TT serves as an unpaid editorial board member of Translational Andrology and Urology from Aug 2019 to Jul 2021. EMK reports receiving honoraria from Janssen and Ipsen; travel & accommodation from Astellas Pharma, Pfizer and Ipsen; and institutional research funding from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Pfizer, and Merck Serono. AAA reports receiving compensation as a Consultant from Astellas Pharma, Janssen, and Novartis; speakers bureau for Astellas, Janssen, Novartis, Amgen, Ipsen, Bristol Myers Squibb, Merck Serono and Bayer; honoraria from Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Telix; Merck Serono; Janssen, Bristol Myers Squibb, Ipsen, Bayer, Pfizer, Amgen, Noxopharm, and Merck Sharpe Dome; research funding from Astellas (investigator), Merck Serono (investigator), Astra Zeneca (investigator), Bristol Myers Squibb (institutional), Astra Zeneca (institutional), Aptevo Therapeutics (institutional), Glaxo Smith Kline (institutional), Pfizer (institutional), MedImmune (institutional), Astellas (institutional), SYNthorx (institutional), Bionomics (institutional), Sanofi Aventis (institutional), Novartis (institutional), and Ipsen (institutional); travel and accommodation from Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar, Pfizer;and is on the Scientific Advisory Board for Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix; Merck Serono; Janssen, Bristol Myers Squibb, Ipsen, Bayer, Merck Sharpe Dome, Amgen and Noxopharm. The other authors have no conflicts of interest to declare.
Références
J Urol. 2016 Dec;196(6):1758-1763
pubmed: 27449259
N Engl J Med. 2019 Jul 11;381(2):121-131
pubmed: 31157964
Cancer Discov. 2018 Apr;8(4):444-457
pubmed: 29367197
Ann Transl Med. 2014 Nov;2(11):107
pubmed: 25489581
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
Clin Cancer Res. 2015 May 15;21(10):2315-24
pubmed: 25712683
Lancet Oncol. 2019 May;20(5):686-700
pubmed: 30987939
Eur Urol Focus. 2021 Jan;7(1):63-70
pubmed: 31103601
Lancet Oncol. 2012 Nov;13(11):1114-24
pubmed: 23059046
World J Urol. 2021 Feb;39(2):339-348
pubmed: 31897602
Endocrinology. 2019 May 1;160(5):1275-1288
pubmed: 30958537
Anticancer Res. 2011 Apr;31(4):1475-82
pubmed: 21508406
Cancer Res. 2017 Jul 1;77(13):3417-3430
pubmed: 28473532
Sci Transl Med. 2015 Nov 4;7(312):312re10
pubmed: 26537258
Eur Urol Oncol. 2018 Dec;1(6):467-475
pubmed: 31158090
J Biol Chem. 2013 Aug 9;288(32):22993-3008
pubmed: 23814079
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):24-38
pubmed: 30131604
J Clin Oncol. 2014 Mar 1;32(7):671-7
pubmed: 24449231
Eur Urol. 2014 Jun;65(6):1191-7
pubmed: 23954088
Lancet Oncol. 2012 Nov;13(11):1105-13
pubmed: 23059047
J Clin Oncol. 2002 Oct 1;20(19):3972-82
pubmed: 12351594
Eur Urol. 2018 Jun;73(6):818-821
pubmed: 29398263
Eur Urol. 2015 Aug;68(2):196-204
pubmed: 25277272
J Natl Cancer Inst. 2017 Dec 1;109(12):
pubmed: 29206995
J Clin Oncol. 2019 Nov 10;37(32):2974-2986
pubmed: 31329516
Eur Urol. 2020 Aug;78(2):173-180
pubmed: 32487321
Acta Cytol. 2019;63(6):479-488
pubmed: 30783027
Eur Urol. 2018 Jun;73(6):847-855
pubmed: 29475737
J Clin Oncol. 2018 Feb 1;36(4):376-382
pubmed: 29261442
JAMA Oncol. 2016 Nov 1;2(11):1441-1449
pubmed: 27262168
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
J Clin Oncol. 2003 Apr 1;21(7):1232-7
pubmed: 12663709
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Eur Urol. 2017 Aug;72(2):192-200
pubmed: 28104311
Ann Oncol. 2017 Jul 1;28(7):1508-1516
pubmed: 28472366
Sci Transl Med. 2014 Sep 17;6(254):254ra125
pubmed: 25232177
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
Cell Cycle. 2017 Apr 3;16(7):693-706
pubmed: 28278050
J Urol. 2003 Jan;169(1):164-9
pubmed: 12478127
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
Clin Chem. 2015 Jun;61(6):809-20
pubmed: 25882892
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
J Urol. 2017 Jan;197(1):135-142
pubmed: 27436429